BioAlliance Pharma Establishes Sales and Marketing Subsidiary to Prepare for Loramyc Launch
Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations. Laboratoires BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc(R), for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005. The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupr?, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.
Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations.
Laboratories BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc,® for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005.
The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupre, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
